Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Short term Debt (2016 - 2020)

Historic Short term Debt for Summit Therapeutics (SMMT) over the last 3 years, with Q1 2020 value amounting to -$102549.2.

  • Summit Therapeutics' Short term Debt changed N/A to -$102549.2 in Q1 2020 from the same period last year, while for Mar 2020 it was -$102549.2, marking a year-over-year change of. This contributed to the annual value of $105000.0 for FY2019, which is N/A changed from last year.
  • According to the latest figures from Q1 2020, Summit Therapeutics' Short term Debt is -$102549.2.
  • In the past 5 years, Summit Therapeutics' Short term Debt registered a high of -$98000.0 during Q3 2019, and its lowest value of -$1.1 million during Q4 2018.
  • For the 3-year period, Summit Therapeutics' Short term Debt averaged around -$449215.7, with its median value being -$102858.0 (2019).
  • The largest annual percentage gain for Summit Therapeutics' Short term Debt in the last 5 years was 9113.38% (2019), contrasted with its biggest fall of 9113.38% (2019).
  • Summit Therapeutics' Short term Debt (Quarter) stood at -$1.1 million in 2018, then soared by 90.79% to -$102858.0 in 2019, then grew by 0.3% to -$102549.2 in 2020.
  • Its Short term Debt stands at -$102549.2 for Q1 2020, versus -$102858.0 for Q4 2019 and -$99015.2 for Q4 2019.